August 6th 2024
A panel of experts offer future perspectives in HR+ breast cancer.
A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.
July 29th 2024
Dr Pegram discusses the use of oral SERDs in HR-positive metastatic breast cancer and biomarker testing practices for patients with metastatic disease.
A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.
A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.
A panel of experts discuss navigating 2L treatment strategies.
A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.
July 8th 2024
A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.
A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.
July 1st 2024
A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.
A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.
June 25th 2024
Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.
Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.
June 7th 2024
Mark Pegram, MD, discusses implications of and safety data from the primary analysis of the DESTINY-Breast06 trial in HR+/HER2– metastatic breast cancer.
September 7th 2022
Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.
A review of when to use the Breast Cancer Index for patients with HR+ breast cancer when deciding on endocrine therapy duration.
August 26th 2022
Experts discuss biomarkers used to determine if a patient with HR+ breast cancer will benefit from extended endocrine therapy.
Lee Schwartzberg, MD, FACP, explains the IDEAL study and data on the benefits of extended adjuvant endocrine therapy in HR+ breast cancer.
August 19th 2022
Drs Schwartzberg and Pegram debate the value of having patients undergo more than 1 multigene assay to predict their risk of recurrence.
Mark Pegram, MD, details the role of biomarkers in predicting recurrences in patients with HR+ breast cancer.